Trials / Completed
CompletedNCT00432380
A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.
Immunogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Liquid Vaccine (GSK 357941A) in Healthy Infants.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 375 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 5 Weeks – 10 Weeks
- Healthy volunteers
- Accepted
Summary
This study will provide data on the immune response and safety of GSK Biologicals' HRV liquid vaccine when given along with the routine infant immunizations in Philippines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Rotarix™ | oral doses |
| BIOLOGICAL | Placebo | oral dose |
Timeline
- Start date
- 2007-03-09
- Primary completion
- 2007-09-04
- Completion
- 2007-09-04
- First posted
- 2007-02-07
- Last updated
- 2020-01-02
- Results posted
- 2017-09-11
Locations
1 site across 1 country: Philippines
Source: ClinicalTrials.gov record NCT00432380. Inclusion in this directory is not an endorsement.